| Year |
Citation |
Score |
| 2021 |
Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. Npj Breast Cancer. 7: 60. PMID 34040000 DOI: 10.1038/s41523-021-00270-4 |
0.396 |
|
| 2020 |
Marczyk M, Patwardhan GA, Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. Cancers. 12. PMID 32911681 DOI: 10.3390/Cancers12092551 |
0.454 |
|
| 2019 |
Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. Scientific Reports. 9: 14934. PMID 31624295 DOI: 10.1038/s41598-019-51453-w |
0.373 |
|
| 2019 |
Qing T, Marczyk M, Wali V, Gunasekharan V, Patwardhan G, Pusztai L, Hatzis C. Abstract P4-03-01: Pathway level complementarity of germline and somatic events in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-03-01 |
0.444 |
|
| 2019 |
Marczyk M, Gunasekharan V, Wali V, Shi W, Patwardhan G, Qing T, Pusztai L, Hatzis C. Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-06-06 |
0.437 |
|
| 2018 |
Hofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Hatzis C, Patwardhan G, Wahlde MV, Butler M, Epstein L, Stavris K, Sturrock T, Au A, et al. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-04-02 |
0.388 |
|
| 2017 |
Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. Oncotarget. 8: 21733-21740. PMID 28423514 DOI: 10.18632/oncotarget.15562 |
0.302 |
|
| 2017 |
Patwardhan GA, Wali VB, Pusztai L, Hatzis C. Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells Cancer Research. 77: 2073-2073. DOI: 10.1158/1538-7445.Am2017-2073 |
0.38 |
|
| 2016 |
Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer. Cancer Research. PMID 27872098 DOI: 10.1158/0008-5472.Can-16-1901 |
0.333 |
|
| 2014 |
Patwardhan GA, Hosain SB, Liu DX, Khiste SK, Zhao Y, Bielawski J, Jazwinski SM, Liu YY. Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. Biochimica Et Biophysica Acta. 1841: 1571-80. PMID 25195822 DOI: 10.1016/J.Bbalip.2014.08.017 |
0.711 |
|
| 2013 |
Liu Y, Patwardhan GA. Abstract 3199: Ceramide restores the expression of wild-type p53 tumor suppressor in mRNA splicing through PP1 and ASF/SF2. Cancer Research. 73: 3199-3199. DOI: 10.1158/1538-7445.Am2013-3199 |
0.708 |
|
| 2011 |
Liu YY, Patwardhan GA, Xie P, Gu X, Giuliano AE, Cabot MC. Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma International Journal of Oncology. 39: 425-431. PMID 21617856 DOI: 10.3892/Ijo.2011.1052 |
0.668 |
|
| 2011 |
Liu YY, Patwardhan GA, Bhinge K, Gupta V, Gu X, Jazwinski SM. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Research. 71: 2276-85. PMID 21278235 DOI: 10.1158/0008-5472.Can-10-3107 |
0.709 |
|
| 2011 |
Patwardhan GA, Liu YY. Sphingolipids and expression regulation of genes in cancer. Progress in Lipid Research. 50: 104-14. PMID 20970453 DOI: 10.1016/J.Plipres.2010.10.003 |
0.687 |
|
| 2010 |
Siddiqui A, Patwardhan GA, Liu YY, Nazzal S. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. International Journal of Pharmaceutics. 400: 251-9. PMID 20816930 DOI: 10.1016/J.Ijpharm.2010.08.044 |
0.623 |
|
| 2010 |
Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, Mehendale H, Cabot MC, Li YT, Jazwinski SM. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Molecular Cancer. 9: 145. PMID 20540746 DOI: 10.1186/1476-4598-9-145 |
0.689 |
|
| 2010 |
Patwardhan G, Gupta V, Huang J, Gu X, Liu YY. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochemical Pharmacology. 80: 72-9. PMID 20298675 DOI: 10.1016/J.Bcp.2010.03.010 |
0.725 |
|
| 2010 |
Gupta V, Patwardhan GA, Zhang QJ, Cabot MC, Jazwinski SM, Liu YY. Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase. Journal of Lipid Research. 51: 866-74. PMID 19826105 DOI: 10.1194/Jlr.D002949 |
0.628 |
|
| 2010 |
Gupta V, Patwardhan GA, Gu X, Rowan B, Jazwinski M, Liu YY. Abstract 4282: The role of glycosphingolipids in the formation of cancer stem cells and drug resistance Cancer Research. 70: 4282-4282. DOI: 10.1158/1538-7445.Am10-4282 |
0.548 |
|
| 2010 |
Patwardhan GA, Gupta V, Hsia S, Gu X, Jazwinski M, Liu Y. Abstract 2569: Disruption of ceramide glycosylation restores p53-dependent apoptosis in p53 mutant drug-resistant cancer cells: Alternative splicing determines the feature of p53 activity Cancer Research. 70: 2569-2569. DOI: 10.1158/1538-7445.Am10-2569 |
0.725 |
|
| 2009 |
Patwardhan GA, Zhang QJ, Yin D, Gupta V, Bao J, Senkal CE, Ogretmen B, Cabot MC, Shah GV, Sylvester PW, Jazwinski SM, Liu YY. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. Plos One. 4: e6938. PMID 19742320 DOI: 10.1371/Journal.Pone.0006938 |
0.703 |
|
| 2008 |
Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, Consoli DP, Cabot MC. A role for ceramide in driving cancer cell resistance to doxorubicin. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 2541-51. PMID 18245173 DOI: 10.1096/Fj.07-092981 |
0.705 |
|
| Show low-probability matches. |